Skip to Content

Butorphanol Tartrate

Class: Opiate Partial Agonists
VA Class: CN101
CAS Number: 58786-99-5

Warning

    Concomitant Use with Benzodiazepines or Other CNS Depressants
  • Concomitant use of opiates with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.416 417 418 700 701 702 703

  • Reserve concomitant use of opiate analgesics and benzodiazepines or other CNS depressants for patients in whom alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy and monitor closely for respiratory depression and sedation.700 703 (See Specific Drugs under Interactions.)

Introduction

Opiate partial agonist; phenanthrene derivative.a b d

Uses for Butorphanol Tartrate

Pain

Relief of pain that is severe enough to require an opiate analgesic and for which alternative treatment options (e.g., nonopiate analgesics) have not been, or are not expected to be, adequate or tolerated.704

Preoperative sedation and analgesia and as a supplement to surgical anesthesia.a

Obstetric analgesia during labor.a

Management of pain associated with migraine headache.113 114 116 122

In equianalgesic doses, parenteral butorphanol is as effective as morphine, meperidine, and pentazocine, but relative potential for abuse reportedly is less than that of codeine or propoxyphene.d

In symptomatic treatment of acute pain, reserve opiate analgesics for pain resulting from severe injuries, severe medical conditions, or surgical procedures, or when nonopiate alternatives for relieving pain and restoring function are expected to be ineffective or are contraindicated.431 432 433 435 Use smallest effective dosage for shortest possible duration since long-term opiate use often begins with treatment of acute pain.411 431 434 435 Optimize concomitant use of other appropriate therapies.432 434 435 (See Managing Opiate Therapy for Acute Pain under Dosage and Administration.)

Butorphanol Tartrate Dosage and Administration

General

Managing Opiate Therapy for Acute Pain

  • Optimize concomitant use of other appropriate therapies.432 434 435

  • When opiate analgesia required, use conventional (immediate-release) opiates in smallest effective dosage and for shortest possible duration, since long-term opiate use often begins with treatment of acute pain.411 431 434 435

  • When sufficient for pain management, use lower-potency opiate analgesics given in conjunction with acetaminophen or an NSAIA on as-needed (“prn”) basis.432

  • For acute pain not related to trauma or surgery, limit prescribed quantity to amount needed for expected duration of pain severe enough to require opiate analgesia (generally ≤3 days and rarely >7 days).411 433 434 435 Do not prescribe larger quantities for use in case pain continues longer than expected;411 432 instead, reevaluate patient if severe acute pain does not remit.411 431 435

  • For moderate to severe postoperative pain, provide opiate analgesic as part of a multimodal regimen that also includes acetaminophen and/or NSAIAs and other pharmacologic (e.g., certain anticonvulsants, regional local anesthetic techniques) and nonpharmacologic therapy as appropriate.430 431 432

  • Oral administration of conventional opiate analgesics generally preferred over IV administration in postoperative patients who can tolerate oral therapy.430 431

  • Scheduled (around-the-clock) dosing frequently is required during immediate postoperative period or following major surgery.430 432 When repeated parenteral administration is required, IV patient-controlled analgesia (PCA) generally is recommended.430 431

Administration

Administer IM, by IV injection, or by nasal inhalation.113

Nasal Administration

Assemble the nasal solution spray pump according to the manufacturer’s instructions.113 Prior to initial use, fully prime the spray pump; reprime pump whenever it has not been used for ≥48 hours.113

Consult the manufacturer’s patient instructions regarding use of the nasal solution spray pump.113 124

The nasal solution spray pump is an open delivery system; aim the pump spray away from the patient, other individuals, or animals to minimize environmental exposure.113

IV Administration

For drug compatibility information, see Compatibility under Stability.

Dosage

Available as butorphanol tartrate; dosage expressed in terms of the salt.a b

After initial priming, the nasal solution spray pump delivers about 14–15 metered doses containing 1 mg per spray.a If repriming of the pump is necessary, the spray pump will deliver about 8–10 metered doses, depending on the extent of repriming.113

Use lowest effective dosage and shortest duration of therapy consistent with treatment goals of the patient.411 413 431 432 435

When used concomitantly with other CNS depressants, use lowest effective dosages and shortest possible duration of concomitant therapy.700 703 (See Specific Drugs under Interactions.)

Adults

Pain
IV

Initially, 1 mg; may repeat dose every 3–4 hours as necessary.a Usual effective dosage, depending on severity of pain, is 0.5–2 mg repeated every 3–4 hours.a

IM

Initially, 2 mg in patients able to remain recumbent; may repeat dose every 3–4 hours as necessary.a Usual effective dosage, depending on severity of pain, is 1–4 mg repeated every 3–4 hours.a

Intranasal

Initially, 1 mg (1 spray in 1 nostril); if adequate analgesia is not achieved, may give an additional 1-mg dose within 60–90 minutes.113 May repeat this initial dose sequence in 3–4 hours, if needed.113

For management of severe pain: Initially, 2 mg (1 spray in each nostril) in patients who can remain recumbent if drowsiness or dizziness occurs.113 Do not administer additional 2-mg doses at intervals <3–4 hours, since the incidence of adverse effects may be increased.113

Preoperative Sedation and Analgesia
IM

Usual dosage is 2 mg administered 60–90 minutes before surgery.a

Supplement to Surgical Anesthesia
IV

2 mg shortly before induction of anesthesia and/or 0.5–1 mg administered during anesthesia in increments up to 0.06 mg/kg (depending on previous administration of sedatives, analgesics, and hypnotic agents).a Usual total dose is 4–12.5 mg (approximately 0.06–0.18 mg/kg).a

Obstetric Analgesia
IV or IM

1–2 mg administered in patients at full term in early labor; may repeat after 4 hours.a Use alternative analgesia if delivery expected within 4 hours.a

Prescribing Limits

Adults

Pain

For acute pain not related to trauma or surgery, limit prescribed quantity to amount needed for the expected duration of pain severe enough to require opiate analgesia (generally ≤3 days and rarely >7 days).411 433 434 435

Some states have set prescribing limits for opiate analgesics (e.g., maximum daily dosages that can be prescribed, dosage thresholds at which consultation with a specialist is mandated or recommended).411 420 421 423

IM

Maximum 4 mg as a single dose.a

Special Populations

Hepatic Impairment

Pain
IV

Initially, 0.5 mg.113 If necessary, repeat dose at an interval of ≥6 hours.113

IM

Initially, 1 mg.113 If necessary, repeat dose at an interval of ≥6 hours.113

Intranasal

Initially, 1 mg (1 spray in 1 nostril); may give an additional 1-mg dose within 90–120 minutes, if necessary.113 May repeat this initial dose sequence at an interval of ≥6 hours.113

Renal Impairment

Patients with renal impairment may receive the same IV, IM, or intranasal dosages as patients with hepatic impairment.113

Geriatric Patients

Geriatric patients may receive the same IV, IM, or intranasal dosages as patients with hepatic impairment.113

Cautions for Butorphanol Tartrate

Contraindications

  • Known hypersensitivity to butorphanol or benzethonium chloride (contained in the multiple-dose vials of the injection or in the nasal solution).a b

Warnings/Precautions

Warnings

Abuse Potential

Possible tolerance, psychologic dependence, and physical dependence.a b d Episodes of abuse associated with all routes of administration, especially nasal administration.a b

Patients with a history of drug or alcohol dependence or abuse are at risk of habituation or dependence; use only with careful surveillance in such patients.a b

Respiratory Effects

Possible respiratory depression, especially in patients with impaired respiration caused by other drugs, uremia, severe infection, severely limited respiratory reserve, bronchial asthma, respiratory obstruction, or cyanosis.a b d Use with caution and in lower dosages in these patients.a b d

Consider offering naloxone when opiate analgesics are prescribed for patients at increased risk of opiate overdosage (e.g., those with history of overdose or substance use disorder, those receiving ≥50 mg of morphine sulfate [or equivalent] daily, those receiving benzodiazepines concomitantly, those with medical conditions that could increase sensitivity to opiates).411 431

Patients Dependent on Opiates

Partial opiate antagonist; not recommended for use in patients physically dependent on opiatesa because of the potential to precipitate symptoms of withdrawal (e.g., anxiety, agitation, mood changes, hallucinations, dysphoria, weakness, diarrhea).128 129

Use with caution in patients who recently received repeated doses of opiate analgesics; allow an adequate period of withdrawal from opiates before initiation of butorphanol therapy.128 129

Concomitant Use with Benzodiazepines or Other CNS Depressants

Concomitant use of opiate agonists or opiate partial agonists, including butorphanol, and benzodiazepines or other CNS depressants (e.g., anxiolytics, sedatives, hypnotics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opiates, alcohol) may result in profound sedation, respiratory depression, coma, and death.416 417 418 700 701 702 703 Substantial proportion of fatal opiate overdoses involve concurrent benzodiazepine use.416 417 418 435 700 701

Reserve concomitant use of butorphanol and other CNS depressants for patients in whom alternative treatment options are inadequate.700 703 (See Specific Drugs under Interactions.)

General Precautions

CNS Depression

Performance of activities requiring mental alertness and physical coordination may be impaired.a b

Concurrent use of other CNS depressants may potentiate CNS depressiona b and may result in profound sedation, respiratory depression, coma, or death.700 703 (See Concomitant Use with Benzodiazepines or Other CNS Depressants under Cautions.)

Adrenal Insufficiency

Adrenal insufficiency reported in patients receiving opiate agonists or opiate partial agonists.400 Manifestations are nonspecific and may include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and hypotension.400

If adrenal insufficiency is suspected, perform appropriate laboratory testing promptly and provide physiologic (replacement) dosages of corticosteroids; taper and discontinue the opiate agonist or partial agonist to allow recovery of adrenal function.400 If the opiate agonist or partial agonist can be discontinued, perform follow-up assessment of adrenal function to determine if corticosteroid replacement therapy can be discontinued.400 In some patients, switching to a different opiate improved symptoms.400

Head Injury and Increased Intracranial Pressure

Adverse effects of opiates may obscure the existence, extent, or course of intracranial pathology.113 Use in patients with head injury only if the potential benefits justify the possible risks.113

Cardiovascular Effects

Possible increased myocardial workload; use in patients with AMI, ventricular dysfunction, or coronary insufficiency only if the potential benefits justify the possible risks.a b

Severe hypertension reported rarely.a b If hypertension occurs, discontinue and administer a hypotensive agent as necessary; butorphanol-induced hypertension reportedly has been managed with naloxone in patients who were not opiate dependent.113

Use cautiously before surgery or anesthesia in hypertensive patients.d

Possible hypotension associated with syncope in patients receiving nasal solution; caution patients against performing activities that may pose risks if hypotension were to occur.113

Biliary Tract Surgery

Safe use in patients about to undergo biliary tract surgery has not been established; use with caution.d

Hypogonadism

Hypogonadism or androgen deficiency reported in patients receiving long-term opiate agonist or opiate partial agonist therapy;400 401 402 403 404 causality not established.400 Manifestations may include decreased libido, impotence, erectile dysfunction, amenorrhea, or infertility.400 Perform appropriate laboratory testing in patients with manifestations of hypogonadism.400

Specific Populations

Pregnancy

Category C.a b

Use of intranasal spray not recommended during labor and delivery.

Lactation

Distributed into milk following parenteral administration, but not in clinically important amounts at usual therapeutic dosages.113

No experience with use of nasal solution in nursing women; estimated that amount of drug distributed into milk will be similar to that when administered parenterally.113 b

Pediatric Use

Safety and efficacy not established in children <18 years of age.a b

Geriatric Use

Select dosage with caution.113 (See Geriatric Patients under Dosage and Administration.)

Possible increased sensitivity to the drug in some geriatric individuals.113

Insufficient experience with the nasal solution in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.b

Hepatic Impairment

Use with caution.a b (See Hepatic Impairment under Dosage and Administration.)

Renal Impairment

Use with caution.a b (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Sedation, dizziness, nausea and/or vomiting.a b

Interactions for Butorphanol Tartrate

Not known whether drugs that affect hepatic microsomal enzymes may interfere with metabolism of butorphanol.113

Drugs Associated with Serotonin Syndrome

Risk of serotonin syndrome when used with other serotonergic drugs.400 May occur at usual dosages.400 Symptom onset generally occurs within several hours to a few days of concomitant use, but may occur later, particularly after dosage increases.400 (See Advice to Patients.)

If concomitant use of other serotonergic drugs is warranted, monitor patients for serotonin syndrome, particularly during initiation of therapy and dosage increases.400

If serotonin syndrome is suspected, discontinue butorphanol, other opiate therapy, and/or any concurrently administered serotonergic agents.400

Specific Drugs

Drug

Interaction

Comments

Antidepressants, SSRIs (e.g., citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), SNRIs (e.g., desvenlafaxine, duloxetine, milnacipran, venlafaxine), tricyclic antidepressants (TCAs), mirtazapine, nefazodone, trazodone, vilazodone

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, the antidepressant, and/or any concurrently administered opiates or serotonergic agents400

Antiemetics, 5-HT3 receptor antagonists (e.g., dolasetron, granisetron, ondansetron, palonosetron)

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, the 5-HT3 receptor antagonist, and/or any concurrently administered opiates or serotonergic agents400

Antipsychotics (e.g., aripiprazole, asenapine, cariprazine, chlorpromazine, clozapine, fluphenazine, haloperidol, iloperidone, loxapine, lurasidone, molindone, olanzapine, paliperidone, perphenazine, pimavanserin, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, ziprasidone)

Risk of profound sedation, respiratory depression, hypotension, coma, or death700 703 704

Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy700 703

In patients receiving butorphanol, initiate antipsychotic, if required, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700 703

In patients receiving an antipsychotic, initiate butorphanol, if required, at reduced dosage and titrate based on clinical response700 703

Monitor closely for respiratory depression and sedation700 703

Benzodiazepines (e.g., alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, triazolam)

Risk of profound sedation, respiratory depression, hypotension, coma, or death416 417 418 700 701 703 704

Whenever possible, avoid concomitant use410 411 415 435

Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy700 703

In patients receiving butorphanol, initiate benzodiazepine, if required for any indication other than epilepsy, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700 703

In patients receiving a benzodiazepine, initiate butorphanol, if required, at reduced dosage and titrate based on clinical response700 703

Monitor closely for respiratory depression and sedation700 703

Consider offering naloxone to patients receiving opiates and benzodiazepines concomitantly411 431

Buspirone

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, buspirone, and/or any concurrently administered opiates or serotonergic agents400

Cimetidine

Pharmacokinetic interaction unlikelyb

CNS depressants (e.g., alcohol, other opiates, antihistamines, general anesthetics, anxiolytics, phenothiazines, tranquilizers, barbiturates)

Additive CNS effects;a b increased risk of profound sedation, respiratory depression, hypotension, coma, or death700 703 704

Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy700 703

In patients receiving butorphanol, initiate CNS depressant, if required for any indication other than epilepsy, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700 703

In patients receiving a CNS depressant, initiate butorphanol, if required, at reduced dosage and titrate based on clinical response700 703

Monitor closely for respiratory depression and sedation700 703

Avoid alcohol use700

Dextromethorphan

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, dextromethorphan, and/or any concurrently administered opiates or serotonergic agents400

Erythromycin

Potential for decreased metabolism of butorphanol is unknown113 a b

Consider reducing dose and increasing interval between doses of butorphanol113 a b

5-HT1 receptor agonists (triptans; e.g., almotriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan)

Risk of serotonin syndrome400

Sumatriptan (intranasal): Reduced analgesic effect of butorphanol nasal spray when administered shortly after sumatriptan nasal spray; possible increased BPb

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, the triptan, and/or any concurrently administered opiates or serotonergic agents400

Sumatriptan (intranasal): Reduction in analgesic effect is minimal if butorphanol is administered ≥30 minutes after sumatriptanb

Lithium

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, lithium, and/or any concurrently administered opiates or serotonergic agents400

MAO inhibitors (e.g., isocarboxazid, linezolid, methylene blue, phenelzine, selegiline, tranylcypromine)

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, the MAO inhibitor, and/or any concurrently administered opiates or serotonergic agents400

Oxymetazoline

Possible decreased rate of absorption of intranasal butorphanol; extent of absorption appears to be unchanged113 b

Slower onset of analgesic action if butorphanol is administered intranasally with or immediately after oxymetazoline113

Pancuronium

Increased conjunctival changesd

Sedative/hypnotic agents (e.g., butabarbital, eszopiclone, pentobarbital, ramelteon, secobarbital, suvorexant, zaleplon, zolpidem)

Risk of profound sedation, respiratory depression, hypotension, coma, or death700 703 704

Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy700 703

In patients receiving butorphanol, initiate sedative/hypnotic, if required, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700 703

In patients receiving a sedative/hypnotic, initiate butorphanol, if required, at reduced dosage and titrate based on clinical response700 703

Monitor closely for respiratory depression and sedation700 703

Skeletal muscle relaxants (e.g., baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, dantrolene, metaxalone, methocarbamol, orphenadrine, tizanidine)

Risk of profound sedation, respiratory depression, hypotension, coma, or death700 703 704

Cyclobenzaprine: Increased risk of adverse effects (e.g., seizures, serotonin syndrome)400

Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy700 703

In patients receiving butorphanol, initiate skeletal muscle relaxant, if required, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700 703

In patients receiving a skeletal muscle relaxant, initiate butorphanol, if required, at reduced dosage and titrate based on clinical response700 703

Monitor closely for respiratory depression and sedation700 703

Cyclobenzaprine: If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, cyclobenzaprine, and/or any concurrently administered opiates or serotonergic agents400

St. John’s wort (Hypericum perforatum)

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, St. John’s wort, and/or any concurrently administered opiates or serotonergic agents400

Theophylline

Potential for decreased metabolism of butorphanol is unknown113 b

Consider reducing dose and increasing interval between doses of butorphanol113 b

Tryptophan

Risk of serotonin syndrome400

If concomitant use warranted, monitor for serotonin syndrome, particularly during initiation of therapy and dosage increases400

If serotonin syndrome suspected, discontinue butorphanol, tryptophan, and/or any concurrently administered opiates or serotonergic agents400

Butorphanol Tartrate Pharmacokinetics

Absorption

Bioavailability

Rapidly absorbed following IM injection; peak plasma concentrations usually attained within 30–60 minutes.a d

Following nasal inhalation, peak blood concentrations are achieved in about 30–60 minutes.113 114 Absolute bioavailability of nasally administered butorphanol is 60–70% and appears to be unchanged in patients with allergic rhinitis.a

Completely absorbed from the GI tract following oral administration; however, after first-pass metabolism, bioavailability is only 5–17%.a b

Onset

Onset of analgesic activity occurs in a few minutes after IV administration or within 15 minutes after IM administration;a b peak analgesic effect achieved within 30–60 minutes after IV or IM administration.a

After nasal inhalation in postoperative patients, onset of analgesia occurs within 15 minutes;113 114 125 peak analgesic effect achieved within 1–2 hours.b

Duration

After IV or IM administration, duration of analgesia is 3–4 hours.a b

After nasal inhalation in postoperative patients, duration of analgesia is approximately 2.5–5 hours.113 114 125

Distribution

Extent

Highest concentrations of butorphanol and its metabolites in animals are found in the liver, kidneys, and intestine; drug concentrations are higher in the lungs, spleen, heart, endocrine tissues, blood cells, and fat tissue than in plasma; brain concentrations are lower than plasma concentrations.d

Rapidly crosses the placenta and is distributed into milk.a b

Plasma Protein Binding

About 80%.a b

Elimination

Metabolism

Extensively metabolized in the liver, principally by hydroxylation; N-dealkylation and conjugation of butorphanol and its metabolites also occur.a b d Metabolites have no analgesic activity.d

Elimination Route

Excreted principally in urine (70–80%) mainly as metabolites; also excreted in feces (15%).a b

Half-life

About 4.6–4.7 hours following intranasal or IV administration.113 114

Special Populations

In patients with hepatic impairment, elimination half-life of 16.8 hours reported.b

In patients with renal impairment (Clcr <30 mL/minute), elimination half-life of 10.5 hours reported.113

In geriatric individuals, elimination half-life reported to be about 5.6 hours (range 3.3–8.8 hours) or 6.6 hours (range: 3.8–9.2 hours) following IV or intranasal administration, respectively.113

Stability

Storage

Nasal

Solution

25°C.b

Parenteral

Injection

15–30°C; protect from light.a

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Drug Compatibility

Y-Site CompatibilityHID

Compatible

Allopurinol sodium

Amifostine

Aztreonam

Bivalirudin

Cefepime HCl

Cladribine

Dexmedetomidine HCl

Docetaxel

Doxorubicin HCl liposome injection

Enalaprilat

Esmolol HCl

Etoposide phosphate

Fenoldopam mesylate

Filgrastim

Fludarabine phosphate

Gemcitabine HCl

Granisetron HCl

Hetastarch in lactated electrolyte injection (Hextend)

Labetalol HCl

Linezolid

Melphalan HCl

Nicardipine HCl

Oxaliplatin

Paclitaxel

Pemetrexed disodium

Piperacillin sodium–tazobactam sodium

Propofol

Remifentanil HCl

Sargramostim

Teniposide

Thiotepa

Vinorelbine tartrate

Incompatible

Amphotericin B cholesteryl sulfate complex

Lansoprazole

Midazolam HCl

Actions

  • Analgesic effect is believed to result from an interaction with an opiate receptor site in the CNS (probably in or associated with the limbic system).a

  • Opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but other mechanisms probably also are involved.d Butorphanol exerts antagonistic114 115 126 or partially antagonistic113 effects at μ opiate receptor sites; it appears to exerts agonistic effects principally at κ and Σ opiate receptors.101 102 103 104

  • Produces respiratory depression, sedation, miosis and, in animals, antitussive effect.a

  • Slightly increases pulmonary artery pressure, pulmonary wedge pressure, left ventricular end-diastolic pressure, systemic arterial pressure, pulmonary vascular resistance, and cardiac index.a

  • In animals, inhibits GI motility slightly, causes little increase in duodenal smooth muscle activity, and has little or no effect on bile duct flow.d

Advice to Patients

  • Potential for butorphanol to impair mental alertness or physical coordination; do not drive or operate machinery for ≥1 hour after receiving the drug or until effects on individual are known.a b

  • Patients receiving the nasal solution should not perform activities that may pose risks if hypotension were to occur.113

  • Importance of taking only as prescribed; do not increase dosage or duration of therapy unless otherwise instructed by a clinician.a b

  • Risk of potentially fatal additive effects (e.g., profound sedation, respiratory depression, coma) if used concomitantly with benzodiazepines or other CNS depressants, including alcohol and other opiates, either therapeutically or illicitly; avoid concomitant use unless such use is supervised by clinician.700 703 Importance of informing patients that butorphanol should not be combined with alcohol.700 a b

  • Potential risk of serotonin syndrome with concurrent use of butorphanol and other serotonergic agents.400 Importance of immediately contacting clinician if manifestations of serotonin syndrome (e.g., agitation, hallucinations, tachycardia, labile BP, fever, excessive sweating, shivering, shaking, muscle stiffness, twitching, loss of coordination, nausea, vomiting, diarrhea) develop.400

  • Potential risk of adrenal insufficiency.400 Importance of contacting clinician if manifestations of adrenal insufficiency (e.g., nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, hypotension) develop.400

  • Possible risk (although causality not established) of hypogonadism or androgen deficiency with long-term opiate agonist or partial agonist use.400 Importance of informing clinician if decreased libido, impotence, erectile dysfunction, amenorrhea, or infertility occurs.400

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and alcohol consumption.a b

  • Importance of women informing their clinician if they are or plan to become pregnant or to breast-feed.a b

  • Importance of advising patients of other important precautionary information.a b (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Subject to control under the Federal Controlled Substances Act of 1970 as a schedule IV (C-IV) drug.127 128 129

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Butorphanol Tartrate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Nasal

Solution

1 mg/metered spray (10 mg/mL)*

Butorphanol Tartrate Nasal Spray ( C-IV)

Parenteral

Injection

1 mg/mL*

Butorphanol Tartrate Injection ( C-IV)

2 mg/mL*

Butorphanol Tartrate Injection ( C-IV)

AHFS DI Essentials. © Copyright 2017, Selected Revisions November 13, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

References

Only references cited for selected revisions after 1984 are available electronically.

100. The United States pharmacopeia, 21st rev, and The national formulary, 16th ed. Rockville, MD: The United States Pharmacopeial Convention, Inc; 1985:141-2.

101. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:491-531.

102. Martin WR. Pharmacology of opioids. Pharmacol Rev. 1983; 35:283-323. [PubMed 6144112]

103. Zola EM, McLeod DC. Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intell Clin Pharm. 1983; 17:411-7. [PubMed 6861632]

104. Lewis JR. Evaluation of new analgesics: butorphanol and nalbuphine. JAMA. 1980; 243:1465-7. [PubMed 7359723]

105. Evans WS, Bowen JN, Giordano FL et al. A case of Stadol dependence. JAMA. 1985; 253:2191-2. [PubMed 3974108]

106. Smith SG, Davis WM. Nonmedical use of butorphanol and diphenhydramine. JAMA. 1984; 252:1010. [PubMed 6748202]

107. Brown GR. Stadol dependence: another case. JAMA. 1985; 254:910. [PubMed 4021020]

108. Austin RP. Diversion of butorphanol. Am J Hosp Pharm. 1983; 40:1306. [PubMed 6614013]

109. Hoover RC, Williams RB. Survey of butorphanol and nalbuphine diversion in U.S. hospitals. Am J Hosp Pharm. 1985; 42:1111-3. [PubMed 4003423]

110. Butorphanol. In: WHO Expert Committee on Drug Dependence. 25th report. Technical report series 775. Geneva: World Health Organization; 1989:24-6.

111. Preston KL, Bigelow GE, Liebson IA. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther. 1988; 246:441-8. [PubMed 2457074]

112. Preston KL, Bigelow GE, Liebson IA. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. NIDA Res Monogr. 1987; 76:157-61. [PubMed 2449617]

113. Mead Johnson. Stadol (butorphanol tartrate) injectable and Stadol NS (butorphanol tartrate) nasal spray prescribing information. Princeton, NJ; 1995 Jan.

114. Gillis JC, Benfield P, Goa KL. Transnasal butorphanol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs. 1995; 50:157-75. [PubMed 7588085]

115. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:485-521.

116. Anon. Drugs for migraine. Med Lett Drugs Ther. 1995; 37:17-20. [PubMed 7862023]

117. Joyce TH, Kubicek MF, Skjonsby BS et al. Efficacy of transnasal butorphanol tartrate in postepisiotomy pain: a model to assess analgesia. Clin Ther. 1993; 15:160-7. [PubMed 8458045]

118. Shyu WC, Morgenthien EA, Pittman KA et al. The effects of age and sex on the systemic availability and pharmacokinetics of transnasal butorphanol. Eur J Clin Pharmacol. 1994; 47:57-60. [PubMed 7988625]

119. Shyu WC, Pittman KA, Robinson DS et al. The absolute bioavailability of transnasal butorphanol in patients experiencing rhinitis. Eur J Clin Pharmacol. 1993; 45:559-62. [PubMed 8157043]

120. Shyu WC, Mayol RF, Pfeffer M et al. Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanol. Biopharm Drug Dispos. 1993; 14:371-9. [PubMed 8218955]

121. Shyu WC, Pittman KA, Robinson D et al. Multiple-dose phase I study of transnasal butorphanol. Clin Pharmacol Ther. 1993; 54:34-41. [PubMed 8330463]

122. Hoffert MJ, Couch JR, Diamond S et al. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995; 35:65-9. [PubMed 7737863]

123. Bristol-Myers Squibb, Princeton, NJ: Personal communication.

124. Mead Johnson. Stadol NS (butorphanol tartrate) nasal spray patient instructions. Princeton, NJ; 1992.

125. Schwesinger WH, Reynolds JC, Harshaw DH et al. Transnasal butorphanol and intramuscular meperidine in the treatment of postoperative pain. Adv Ther. 1992; 9:123-9.

126. Chen JC, Smith ER, Cahill M et al. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1992; 52:389-96.

127. Code of federal regulations. Part 1308. Schedules of controlled substances, revised as of April 1, 1998.

128. Bristol-Myers Squibb. Stadol NS (butorphanol tartrate) nasal spray prescribing information. Priceton, NJ; 1999 May.

129. Bristol-Myers Squibb, Priceton, NJ: Personal communication.

130. Matchar DB, Young WB, Rosenberg JH et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attaks. St. Paul, MN; 2001. From the American Academy of Neurology web site: ().

400. US Food and Drug Administration. Drug safety communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Silver Spring, MD; 2016 Mar 22. From FDA website.

401. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009; 25:170-5. [PubMed 19333165]

402. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004; 100:851-8. [PubMed 14770444]

403. Abs R, Verhelst J, Maeyaert J et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000; 85:2215-22. [PubMed 10852454]

404. Fraser LA, Morrison D, Morley-Forster P et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009; 117:38-43. [PubMed 18523930]

410. Nuckols TK, Anderson L, Popescu I et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160:38-47. [PubMed 24217469]

411. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016; 65:1-49. [PubMed 26987082]

413. Management of Opioid Therapy for Chronic Pain Working Group, US Department of Veterans Affairs and Department of Defense. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. 2010 May.

415. Manchikanti L, Abdi S, Atluri S et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician. 2012; 15(3 Suppl):S67-116.

416. Park TW, Saitz R, Ganoczy D et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015; 350:h2698. [PubMed 26063215]

417. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015; 49:493-501. [PubMed 26143953]

418. Dasgupta N, Funk MJ, Proescholdbell S et al. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain Med. 2016; 17:85-98. [PubMed 26333030]

420. National Alliance for Model State Drug Laws (NAMSLD). Overview of state pain management and prescribing policies. From NAMSLD webiste. Accessed 2016 Sep 14.

421. Bennett A (Maine Office of Governor). Augusta, ME: 2016 Apr 19. Governor signs major opioid prescribing reform bill. Press release.

423. Franklin GM, American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014; 83:1277-84. [PubMed 25267983]

430. Chou R, Gordon DB, de Leon-Casasola OA et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016; 17:131-57. [PubMed 26827847]

431. Washington State Agency Medical Directors' Group (AMDG). Interagency guideline on prescribing opioids for pain, 3rd ed. From Washington State AMDG website. 2015 Jun.

432. Hegmann KT, Weiss MS, Bowden K et al. ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med. 2014; 56:e143-59.

433. Cantrill SV, Brown MD, Carlisle RJ et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med. 2012; 60:499-525. [PubMed 23010181]

434. Thorson D, Biewen P, Bonte B et al, for Institute for Clinical Systems Improvement (ICSI). Acute pain assessment and opioid prescribing protocol. From ICSI website. 2014 Jan.

435. New York City Department of Health and Mental Hygiene. New York City emergency department discharge opioid prescribing guidelines. From NYC Health website. 2013 Jan.

700. US Food and Drug Administration. Drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD; 2016 Aug 31. From FDA website.

701. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309:657-9. [PubMed 23423407]

702. Jones CM, Paulozzi LJ, Mack KA et al. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010. MMWR Morb Mortal Wkly Rep. 2014; 63:881-5. [PubMed 25299603]

703. Hertz S. Letter to manufacturers of opioid analgesics: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20.

704. Mylan Pharmaceuticals. Butorphanol tartrate nasal spray prescribing information. Morgantown, WV; 2016 Dec.

a. Bedford Laboratories. Butorphanol tartrate injection prescribing information. Bedford OH; 1999 Dec.

b. Bristol-Myers Squibb. Stadol NS (butorphanol tartrate) nasal spray prescribing information. Priceton, NJ; 2002 Mar

HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:233-7.

d. AHFS Drug Information 2004. McEvoy GK, ed. Butorphanol. Bethesda, MD: American Society of Health-System Pharmacists; 2004:2075-7.

Hide